IP Library Granted Patent US 11,066,686
Granted Patent B2
US 11,066,686 · App. 16/657,122 · Granted Jul 20, 2021

RNA polymerase variants

Inventors: Amy E. Rabideau (Waltham, MA); Athanasios Dousis (Cambridge, MA); Kanchana Ravichandran (Cambridge, MA); Elissa Hobert (Cambridge, MA)
Assignee: ModernaTX, Inc.
C12P19/34C12N9/1247C12Y207/11023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,066,686
App. No.
16/657,122
Granted
Jul 20, 2021
Kind
B2
Abstract

The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.

Claims (13)

1. A method of performing an in vitro transcription (IVT) reaction, comprising combining a deoxyribonucleic acid (DNA) with a T7 ribonucleic acid (RNA) polymerase, nucleoside triphosphates and buffer, wherein the T7 RNA polymerase variant comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an amino acid substitution at position 47, and the T7 RNA polymerase variant has RNA polymerase activity.

2. The method of claim 1 , wherein the amino acid substitution is selected from the group consisting of alanine, isoleucine, leucine, methionine, lysine, glutamine, and glutamate.

3. The method of claim 2 , wherein the amino acid substitution is alanine.

4. The method of claim 1 , wherein the T7 RNA polymerase variant comprises an amino acid sequence having at least 95% identity to SEQ ID NO:1.

5. The method of claim 1 , wherein the T7 RNA polymerase comprises an additional C-terminal amino acid.

6. The method of claim 5 , wherein the additional C-terminal amino acid comprises glycine (G).

7. The method of claim 1 , wherein the T7 RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 3.

8. The method of claim 5 , wherein the T7 RNA polymerase comprises two additional C-terminal amino acids.

9. The method of claim 8 , wherein the two additional C-terminal amino acids comprise the same type of amino acid.

10. The method of claim 8 , wherein the two additional C-terminal amino acids comprise two different types of amino acids.

11. A method of performing an in vitro transcription (IVT) reaction, comprising combining a deoxyribonucleic acid (DNA) with a T7 ribonucleic acid (RNA) polymerase, nucleoside triphosphates and buffer, wherein the T7 RNA polymerase variant comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an alanine at position 47, and the T7 RNA polymerase variant has RNA polymerase activity.

12. The method of claim 11 , wherein the T7 RNA polymerase variant further comprises a C-terminal glycine.

13. The method of claim 12 , wherein the T7 RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 110.

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2020
From: RABIDEAU, AMY E.; DOUSIS, ATHANASIOS; RAVICHANDRAN, KANCHANA; HOBERT, ELISSA
To: MODERNATX, INC.
Reel/Frame 051807/0274 →